254 related articles for article (PubMed ID: 36877373)
41. Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías-Vericat JE; Ballesta-López O; Barragán E; Martínez-Cuadrón D; Montesinos P
Blood Rev; 2020 Nov; 44():100675. PubMed ID: 32147087
[TBL] [Abstract][Full Text] [Related]
42. Incorporating FLT3 inhibitors in the frontline treatment of FLT3 mutant acute myeloid leukemia.
Wang ES
Best Pract Res Clin Haematol; 2019 Jun; 32(2):154-162. PubMed ID: 31203997
[TBL] [Abstract][Full Text] [Related]
43. Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.
Reed DR; Sen JM; Pierce EJ; Elsarrag RZ; K Keng M
J Oncol Pharm Pract; 2020 Jul; 26(5):1200-1212. PubMed ID: 32338136
[TBL] [Abstract][Full Text] [Related]
44. RSK Inhibition Induces Apoptosis by Downregulating Protein Synthesis in a Variety of Acute Myeloid Leukemia Cell Lines.
Katayama K; Nishihata A
Biol Pharm Bull; 2021 Dec; 44(12):1843-1850. PubMed ID: 34602526
[TBL] [Abstract][Full Text] [Related]
45. FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.
Larrosa-Garcia M; Baer MR
Mol Cancer Ther; 2017 Jun; 16(6):991-1001. PubMed ID: 28576946
[TBL] [Abstract][Full Text] [Related]
46. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
[TBL] [Abstract][Full Text] [Related]
47. Genomic analysis in myeloid sarcoma and comparison with paired acute myeloid leukemia.
Greenland NY; Van Ziffle JA; Liu YC; Qi Z; Prakash S; Wang L
Hum Pathol; 2021 Feb; 108():76-83. PubMed ID: 33232718
[TBL] [Abstract][Full Text] [Related]
48. FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
Grunwald MR; Levis MJ
Int J Hematol; 2013 Jun; 97(6):683-94. PubMed ID: 23613268
[TBL] [Abstract][Full Text] [Related]
49. Advancing treatment of acute myeloid leukemia: the future of FLT3 inhibitors.
Elshoury A; Przespolewski A; Baron J; Wang ES
Expert Rev Anticancer Ther; 2019 Mar; 19(3):273-286. PubMed ID: 30681373
[TBL] [Abstract][Full Text] [Related]
50. [FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].
Kawashima N
Rinsho Ketsueki; 2021; 62(8):954-966. PubMed ID: 34497236
[TBL] [Abstract][Full Text] [Related]
51. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia.
Weis TM; Marini BL; Bixby DL; Perissinotti AJ
Crit Rev Oncol Hematol; 2019 Sep; 141():125-138. PubMed ID: 31279288
[TBL] [Abstract][Full Text] [Related]
52. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?
Levis M
Hematology Am Soc Hematol Educ Program; 2013; 2013():220-6. PubMed ID: 24319184
[TBL] [Abstract][Full Text] [Related]
53. FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Illmer T; Ehninger G
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S24-34. PubMed ID: 18282363
[TBL] [Abstract][Full Text] [Related]
54. Quizartinib in the treatment of FLT3-internal-tandem duplication-positive acute myeloid leukemia.
Paul S; DiPippo AJ; Ravandi F; Kadia TM
Future Oncol; 2019 Dec; 15(34):3885-3894. PubMed ID: 31559849
[TBL] [Abstract][Full Text] [Related]
55. The molecular mechanisms behind activation of FLT3 in acute myeloid leukemia and resistance to therapy by selective inhibitors.
Friedman R
Biochim Biophys Acta Rev Cancer; 2022 Jan; 1877(1):188666. PubMed ID: 34896257
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
Gebru MT; Wang HG
J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
[TBL] [Abstract][Full Text] [Related]
57. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
Daver N; Cortes J; Kantarjian H; Ravandi F
Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
[TBL] [Abstract][Full Text] [Related]
58. The role of autophagy in targeted therapy for acute myeloid leukemia.
Du W; Xu A; Huang Y; Cao J; Zhu H; Yang B; Shao X; He Q; Ying M
Autophagy; 2021 Oct; 17(10):2665-2679. PubMed ID: 32917124
[TBL] [Abstract][Full Text] [Related]
59. Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Smith CC; Viny AD; Massi E; Kandoth C; Socci ND; Rapaport F; Najm M; Medina-Martinez JS; Papaemmanuil E; Tarver TC; Hsu HH; Le MH; West B; Bollag G; Taylor BS; Levine RL; Shah NP
Clin Cancer Res; 2021 Jul; 27(14):4003-4011. PubMed ID: 34103301
[TBL] [Abstract][Full Text] [Related]
60. Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Baker SD; Zimmerman EI; Wang YD; Orwick S; Zatechka DS; Buaboonnam J; Neale GA; Olsen SR; Enemark EJ; Shurtleff S; Rubnitz JE; Mullighan CG; Inaba H
Clin Cancer Res; 2013 Oct; 19(20):5758-68. PubMed ID: 23969938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
